The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and ...

The heavy selling pressure might have exhausted for Cassava Sciences (SAVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...

While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related ...

Charles Schwab Investment Management Inc. cut its stake in shares of Cassava Sciences, Inc. (NASDAQ:SAVA – Free Report) by 11.6% in the 4th quarter, according to its most recent filing with the ...

The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...

Cassava Sciences (NASDAQ:SAVA – Get Free Report)‘s stock had its “neutral” rating restated by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $2.00 target ...

U.S. stock indices slump amid tariff talks while healthcare sees major developments: J&J faces a $1.6B lawsuit, new FDA approvals, and a $2B ...

NEW YORK (Reuters) -The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who expressed doubts about its experimental, soon ...

US biotech Cassava Sciences (Nasdaq: SAVA) will shut down development of its lead Alzheimer’s disease candidate, simufilam, after the treatment failed a second late-stage trial. Top-line results from ...

NEW YORK (Reuters) -The biotechnology company Cassava Sciences (NASDAQ:SAVA) failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who expressed doubts about its ...